A phase 1 clinical trial of a new cellular immunotherapy being developed in Australia for the treatment of multiple sclerosis (MS) has found that it improved symptoms and quality of life for the majority of patients. …
Latest Video
New Stories
-
New leadership for Mundipharma ANZ with Jane Orr announcing retirement
December 6, 2019 - - Latest News -
AusBiotech 'astonished' after R&D tax cut legislation tabled on final day
December 6, 2019 - - Latest News -
GSK welcomes new approvals for asthma biologic
December 6, 2019 - - Latest News -
NZ to fund AZ's ovarian cancer therapy, finally
December 6, 2019 - - Latest News -
New patient alliance calls for independent review of HTA
December 5, 2019 - - Latest News -
Artificial intelligence to feature at BioPharmaDispatch 2020
December 5, 2019 - - Latest News -
CSL highlights pipeline at investor briefing
December 5, 2019 - - Latest News